| NCT ID | NCT06487247 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 700 participants |
| Start Date | 2025-09-10 |
| Primary Completion | 2029-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 700 participants in total. It began in 2025-09-10 with a primary completion date of 2029-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
Eligibility Criteria
Inclusion Criteria for Patient Participants: * Diagnosis of a relapsed/refractory hematologic malignancy * Age ≥ 18 years * Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment) * Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction * Patient resides within catchment served by Care Dimensions Hospice * Physician-estimated prognosis of six months or less Inclusion Criteria for Caregivers: * Identified informal caregiver of enrolled patient with hematologic malignancy * Age ≥ 18 years Exclusion Criteria for Patient Participants: * Age \< 18 years * Already enrolled in hospice * Resides in nursing home or assisted living facility * History of previous serious adverse transfusion reaction Exclusion Criteria for Caregivers: -Age \< 18 years
Contact & Investigator
Oreofe Odejide, MD, MPH
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06487247 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06487247 currently recruiting?
Yes, NCT06487247 is actively recruiting participants. Contact the research team at Oreofe_Odejide@dfci.harvard.edu for enrollment information.
Where is the NCT06487247 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States.
Who is sponsoring the NCT06487247 clinical trial?
NCT06487247 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Oreofe Odejide, MD, MPH at Dana-Farber Cancer Institute. The trial plans to enroll 700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.